A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
← catalyst calendarNCT06903338 · readout in 134 d
Sponsored by Vir Biotechnology, Inc. (industry) · VIR — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
124actual
Sites
39
Countries
Canada, Georgia, Germany +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-12 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Viral Hepatitis
Interventions
- Drug: Tobevibart — also filed as VIR-3434
- Drug: Elebsiran — also filed as VIR-2218
Primary outcomes
what the primary-completion date above is the date OFHDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2
measured Up to 48 weeks
Incidence of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 12
measured Up to 12 weeks
Publications
- PMID 41586499 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · VIR's whole pipeline · Catalyst calendar · Every registered study · What changed